These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38145237)

  • 21. Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years' Experience 1991-2015.
    Almalki ZS; Yue X; Xia Y; Wigle PR; Guo JJ
    Pharmacoecon Open; 2017 Jun; 1(2):123-131. PubMed ID: 29442334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
    Boyer S; Baudoin M; Nishimwe ML; Santos M; Lemoine M; Maradan G; Sylla B; Kouanfack C; Carrieri P; Mourad A; Rouveau N; Moh R; Seydi M; Attia A; Woode ME; Lacombe K
    BMC Health Serv Res; 2022 Mar; 22(1):303. PubMed ID: 35248039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
    Auty SG; Shafer PR; Griffith KN
    JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
    Costa LSD; Alsultan MM; Hincapie AL; Guo JJ
    J Thromb Thrombolysis; 2023 Feb; 55(2):339-345. PubMed ID: 36401731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
    Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
    APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore.
    Wong YJ; Cheen MH; Hsiang JC; Kumar R; Tan J; Teo EK; Thurairajah PH
    JGH Open; 2019 Jun; 3(3):210-216. PubMed ID: 31276038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ
    J Viral Hepat; 2018 Jun; 25(6):640-648. PubMed ID: 29274192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
    Du P; Wang X; Kong L; Jung J
    Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
    Auty SG; Shafer PR; Dusetzina SB; Griffith KN
    JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.
    Gowda C; Lott S; Grigorian M; Carbonari DM; Saine ME; Trooskin S; Roy JA; Kostman JR; Urick P; Lo Re V
    Open Forum Infect Dis; 2018 Jun; 5(6):ofy076. PubMed ID: 29977955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).
    Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S
    JHEP Rep; 2023 Mar; 5(3):100665. PubMed ID: 36686592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.
    Clements KM; Kunte PS; Clark MA; Gurewich D; Greenwood BC; Sefton L; Pratt C; Person SD; Wessolossky MA
    Health Serv Res; 2022 Dec; 57(6):1312-1320. PubMed ID: 35466398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
    BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.